Key Points
- Insider sale: Rapport insider David Bredt sold 8,500 shares on Dec. 15 at an average price of $30.02 for $255,170, reducing his stake to 392,642 shares (a 2.12% ownership decrease); he also sold 8,500 shares in both October and November at about $25.79 and $25.19.
- Market context: RAPP was trading up ~3.9% around $30.76, with a $1.47 billion market cap, 50‑ and 200‑day SMAs of $27.15 and $20.52, and a one‑year range of $6.43–$42.27.
- Analyst and institutional interest: The stock has a consensus "Moderate Buy" rating with a $47.80 price target, and several hedge funds (notably Vestal Point and Polar Capital) recently established large new stakes of about $28M each.
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of the company's stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $30.02, for a total value of $255,170.00. Following the transaction, the insider directly owned 392,642 shares of the company's stock, valued at $11,787,112.84. This represents a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
David Bredt also recently made the following trade(s):
- On Monday, November 17th, David Bredt sold 8,500 shares of Rapport Therapeutics stock. The shares were sold at an average price of $25.19, for a total value of $214,115.00.
- On Wednesday, October 15th, David Bredt sold 8,500 shares of Rapport Therapeutics stock. The shares were sold at an average price of $25.79, for a total transaction of $219,215.00.
Rapport Therapeutics Trading Up 3.9%
Rapport Therapeutics stock opened at $30.76 on Wednesday. The company has a market cap of $1.47 billion, a P/E ratio of -11.35 and a beta of 1.63. The company has a fifty day simple moving average of $27.15 and a 200 day simple moving average of $20.52. Rapport Therapeutics, Inc. has a 1-year low of $6.43 and a 1-year high of $42.27.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.06. On average, equities research analysts forecast that Rapport Therapeutics, Inc. will post -3.65 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have commented on RAPP. The Goldman Sachs Group upgraded shares of Rapport Therapeutics to a "strong-buy" rating in a research note on Friday, September 12th. Wall Street Zen raised Rapport Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday. Citizens Jmp boosted their price target on Rapport Therapeutics from $77.00 to $80.00 and gave the company a "market outperform" rating in a research note on Friday, November 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Rapport Therapeutics in a research note on Wednesday, October 8th. Finally, Truist Financial initiated coverage on Rapport Therapeutics in a report on Tuesday, September 16th. They set a "buy" rating and a $44.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $47.80.
Check Out Our Latest Analysis on RAPP
Hedge Funds Weigh In On Rapport Therapeutics
A number of hedge funds have recently modified their holdings of the business. Tudor Investment Corp ET AL acquired a new stake in Rapport Therapeutics in the third quarter valued at $331,000. Maven Securities LTD acquired a new position in Rapport Therapeutics in the third quarter valued at $594,000. Wilmington Savings Fund Society FSB bought a new stake in Rapport Therapeutics during the third quarter valued at $143,000. Vestal Point Capital LP bought a new position in shares of Rapport Therapeutics in the 3rd quarter worth about $28,215,000. Finally, Polar Capital Holdings Plc bought a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at about $27,887,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
